Valion Bio, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael R. Cavanaugh
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1305 E. Houston Street San Antonio TX United States of America 78205
- IPO Date
- Nov 11, 2021
- CIK
- 0001787740
- Website
- valionbio.com
- Similar Companies
- Business
- Malachite Innovations, Inc. (OTC: VBIO/MLCT/RNGE) operates as a holding company focused on impact investing to address environmental, social, and health challenges, primarily through acquiring, reclaiming, and repurposing mine sites and undervalued land in economically disadvantaged communities throughout Appalachia; its core operating businesses include Range Reclaim, providing land reclamation, water restoration, and environmental consulting services via subsidiaries Range Environmental Resources, Inc. and Collins Building & Contracting, Inc.; Range Minerals, offering land reclamation and incidental mining services through Range Natural Resources, Inc.; Range Security, delivering eco-friendly, technology-driven security services via Range Security Resources, LLC; Range Water, developing biochar products for water treatment and agricultural solutions through Terra Preta, LLC; and Range Land, focused on land acquisition and repurposing for commercial, industrial, and recreational uses via CLV Azurite Land, LLC; the company also maintains a legacy cannabinoid drug development program under Graphium Biosciences, Inc., advancing tetrahydrocannabinol glycoside (VBX-100) prodrug candidates for inflammatory bowel disease, irritable bowel syndrome, and pediatric ulcerative colitis, supported by FDA Orphan Drug Designation, additional animal studies, and patent filings. Founded in 2007 and headquartered in Cleveland, Ohio, the company serves mining and non-mining industries across Appalachia with cash flow-positive operations generating aggregate revenues exceeding $15 million in recent periods. In recent developments, Malachite Innovations changed its name to Range Impact, Inc. and adopted the ticker symbol RNGE in December 2023 to align with its impact investing strategy following the planned spin-out of Graphium Biosciences via an investment banking engagement; it closed $1.0 million and $1.7 million capital raises in September and December 2023, respectively, to fund mine land acquisitions including 1,600 acres through new subsidiary Catalyst Land Ventures, LLC; executed $3.0 million raise and initial ESG acquisitions of Range entities in 2022; launched expansions like Terra Preta consultant hires and Fola Mine Complex investments; and originated from Vitality Biopharma, Inc. (formerly Stevia First Corp.) with a 2021 corporate restructuring that shifted headquarters from Los Angeles, California, synchronized fiscal year-end to December 31, and established dual-track operations in ESG and biotech.
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
Valion Bio Appoints Melinda Lackey as General Counsel
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility